Storia in 6 fonti

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3 study, showing higher skin clearance rates.

Raccontata dabiopharmadive.comfiercebiotech.commorningstar.comendpoints.newsbenzinga.comhealio.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo2 g fa

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3 study, showing higher skin clearance rates.

originale

biopharmadive.com3 g fa

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Zasocitinib outperformed Sotyktu 2.5x on complete psoriasis clearance, validating Takeda's $4B drug-discovery acquisition. The result signals market shift toward oral therapies, expected to triple in a decade, reshaping competitive strategy and budget allocation in biopharma.

Leggi questa versione → originale

fiercebiotech.com2 g fa

Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year. | Takeda has won the battle of the TYK2…

Leggi questa versione → originale

morningstar.com2 g fa

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study,…

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Leggi questa versione → originale

healio.com2 g fa

Topline data: Zasocitinib outperforms deucravacitinib for plaque psoriasis

Zasocitinib outperformed deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis, according to topline data. As Healio previously reported, zasocitinib (Takeda) is an investigational,…

Leggi questa versione → originale

endpoints.news2 g fa

Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3

Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study.

Leggi questa versione → originale

Timeline cronologica

1. giovedì 11 giugno 2026·biopharmadive.com
   

   Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

   The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.

2. giovedì 11 giugno 2026·fiercebiotech.com
   

   Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

   Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year. |…

3. giovedì 11 giugno 2026·morningstar.com
   

   Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral…

   Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

4. giovedì 11 giugno 2026·endpoints.news
   

   Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3

   Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study.

5. giovedì 11 giugno 2026·benzinga.com
   

   Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:

   Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3 study, showing higher skin clearance rates.

6. venerdì 12 giugno 2026·healio.com
   

   Topline data: Zasocitinib outperforms deucravacitinib for plaque psoriasis

   Zasocitinib outperformed deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis, according to topline data. As Healio previously reported,…